NEJM Publishes Final Phase 3 VISIONARY Analysis of Sibeprenlimab in IgA Nephropathy
Start here
The New England Journal of Medicine has published online ahead of print the final analysis of the phase 3 VISIONARY trial, evaluating sibeprenlimab in patients with IgA nephropathy. The paper reports the trial's efficacy and safety outcomes for the anti-APRIL antibody, marking the completion of the program's pivotal-stage evidence base. As an ahead-of-print release, formal publication in a print issue is still pending, and further detail on secondary endpoints, long-term safety, and regulatory positioning is expected as the full data are digested by the nephrology community.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- nejm.orgPickSibeprenlimab in IgA Nephropathy — Final Phase 3 Trial Analysis
The NEJM published online ahead of print the final analysis of the phase 3 VISIONARY trial, reporting efficacy and safety results of sibeprenlimab in IgA nephropathy.
Heat trend for this story
Heat now 4·Peak in the comparable set 10 (Oct 22 10:00)·Change over 24h in the comparable set -51%·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.